Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
|
|
PROLUNG INC (LUNG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/28/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/04/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/03/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/03/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/15/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/08/2022 |
8-K
| Quarterly results |
| 02/02/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"About IONIQ Sciences, Inc. IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics or bioimpedance technology and Artificial Intelligence . IONIQ Science’ s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For further information about IONIQ Sciences, Inc., please contact: Andy Robertson | 1-801-736-0729 | [email protected] IONIQ Sciences, Vice President of Business Development IONIQ Sciences, Inc. 350 W. 800 N., Suite 214 S..." |
|
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/07/2021 |
8-K
| Appointed a new director|
Docs:
|
"IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. , is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today IONIQ Sciences announced the appointment of Aaron B. Dorny to its Board of Directors. Mr. Jared Bauer, CEO, stated, “On behalf of the IONIQ Sciences Board of Directors, we are delighted to welcome Mr. Dorny to the Board. We believe that his deep understanding of our life science business and proven financial acumen with companies large and small will greatly help us achieve our goals. Mr. Dorny’ s contributions to our company over the pas..." |
|
| 08/16/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/14/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/28/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/25/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/24/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/14/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/03/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 03/15/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 12/21/2020 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 09/16/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
| 08/25/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
| 07/15/2020 |
10-K
| Annual Report for the period ended December 31, 2019 |
| 05/28/2020 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits|
Docs:
|
"ProLung announces corporate name change to IONIQ Sciences to reflect expanded early cancer detection strategy Salt Lake City, UT, May 27, 2020 – IONIQ Sciences Inc. , which is changing the cancer landscape with a modern multi-cancer screening technology using its non-invasive Electrical Impedance Analytics technology and a proprietary algorithm, announced it is changing its name from ProLung, Inc. to IONIQ Sciences, Inc. . The new corporate name – IONIQ Sciences – reflects its mission to dramatically improve the cancer landscape with a modern solution for the early detection of multiple cancers thereby expanding the therapeutic window, significantly improving survivability, and reducing the cost of healthcare. IONIQ Sciences remains fully committed to gaining U.S. FDA regulatory clearance ...",
"IONIQ Sciences announces institutional offering Salt Lake City, UT, May 28, 2020 – IONIQ Sciences Inc. , announced it is initiating an institutional private equity offering on the heels of receiving ‘Breakthrough Device Designation’ from the U.S. FDA for its lung cancer test. IONIQ Sciences has also re-branded from ProLung, Inc. to IONIQ Sciences, Inc. to reflect its mission to dramatically improve the cancer landscape with a modern solution for the early detection of cancer thereby expanding the therapeutic window, significantly improving survivability, and reducing the cost of healthcare. Proceeds from the offering are intended to fund the company’ s expansion into developing additional single cancer tests and a multi-cancer screen. The securities to be offered in the institutional..." |
|
| 05/22/2020 |
8-K
| Unregistered Sales of Equity Securities |
| 05/08/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2019 |
| 03/10/2020 |
8-K
| Quarterly results |
| 03/04/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2019 |
|
|
|